论文部分内容阅读
目的:探讨应用血清白介素(IL)-23对不同治疗阶段前列腺癌进展的预测价值。方法:收集2018年6月至2019年3月北京医院门诊及住院确诊的转移性前列腺癌患者共124例，根据欧洲泌尿外科前列腺癌指南TNM分期标准对确诊患者进行分期，并分别检测转移性去势抵抗型前列腺癌(mCRPC)组、转移性去势敏感型前列腺癌(mCSPC)组、良性前列腺增生组患者的血清IL-23水平，并对mCSPC患者根据病情是否稳定分组，两组患者血清IL-23水平进行亚组分析，各组患者IL-23水平均结合患者的Gleason评分、前列腺特异性抗原(PSA)水平进行分析比较。结果:mCRPC组患者血清IL-23中位数为79.73(45.61，95.63)μg/L，明显高于良性前列腺增生组中位数30.88(15.01，44.94)μg/L(n Z＝22.66，n P＝0.000)及mCSPC组46.10(35.27，80.92)μg/L(n Z＝11.46，n P＝0.001)；mCSPC组较良性前列腺增生组血清IL-23水平明显升高(n Z＝7.17，n P＝0.007)。亚组分析结果显示，mCRPC病情不稳定组患者血清IL-23中位值110.25(88.47，159.09)μg/L，明显高于mCRPC病情稳定组患者血清IL-23中位值46.52(44.97，80.33)μg/L(n Z＝33.99，n P＝0.000)。mCRPC病情稳定组血清IL-23水平46.52(44.97，80.33)μg/L，与mCSPC组患者46.10(35.27，80.92)μg/L比较差异无统计学意义(n Z＝0.35，n P＝0.554)。n 结论:血清IL-23可作为预示mCSPC治疗效果及预警肿瘤转移的一个潜在生物学指标。“,”Objective:To investigate the value of serum IL-23 in predicting the progression of prostate cancer at different stages of treatment.Methods:A total of 124 patients with metastatic prostate cancer diagnosed in Beijing Hospital from June 2018 to March 2019 were collected.Patients were TNM-staged according to the Prostate Cancer Guidelines of the European Association of Urology.Serum IL-23 levels were measured in patients with metastatic castration resistance prostate cancer(mCRPC), metastatic castration sensitive prostate cancer(mCSPC)and benign prostatic hyperplasia(BPH), respectively.Patients with mCRPC were subgrouped based on disease stability, and serum IL-23 levels were compared between the subgroups.Serum IL-23 levels in the groups were analyzed and compared with the Gleason score and the prostate-specific antigen(PSA)level.Results:The median value of serum IL-23 in the mCRPC group was 79.73(45.61, 95.63)μg/L, which was higher than that in the BPH group[30.88(15.01, 44.94)μg/L,n Z=22.66, n P=0.000]and the mCSPC group[46.10(35.27, 80.92)μg/L,n Z=11.46, n P=0.001]. Serum IL-23 levels were higher in the mCSPC group than in the BPH group(n Z=7.17, n P=0.007). Analysis for the subgroups showed that the median value of serum IL-23 was 110.25(88.47, 159.09)μg/L in mCRPC patients with unstable disease, which was higher than that in mCRPC patients with stable disease[46.52(44.97, 80.33)μg/L,n Z=33.99, n P=0.000]. There was no significant difference in serum IL-23 levels between mCRPC patients with stable disease and mCSPC patients[46.10(35.27, 80.92)μg/L](n Z=0.35, n P=0.554).n Conclusions:Serum IL-23 can be used as a potential biological indicator to predict the therapeutic effect of mCSPC and to predict tumor metastasis.